AVXL, NasdaqGS

Anavex Life Sciences Corp. (AVXL)

Price (as of October 26)

11.87USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

CING

Cingulate Inc.

-0.16

CRBU

Caribou Biosciences, Inc.

-0.14

CINC

CinCor Pharma, Inc.

-0.11

IMGO

Imago BioSciences, Inc.

-0.09

AMLX

Amylyx Pharmaceuticals, Inc.

-0.08

FBIOP

Fortress Biotech, Inc.

-0.07

ANTX

AN2 Therapeutics, Inc.

-0.07

ATHA

Athira Pharma, Inc.

-0.07

INZY

Inozyme Pharma, Inc.

-0.07

ANGN

Angion Biomedica Corp.

-0.06

Show more

Highest within Industry

Symbol Correlation

BEAM

Beam Therapeutics Inc.

0.38

BDTX

Black Diamond Therapeutics, Inc.

0.27

AUTL

Autolus Therapeutics plc

0.24

AVTE

Aerovate Therapeutics, Inc.

0.24

AURA

Aura Biosciences, Inc.

0.23

BCAB

BioAtla, Inc.

0.23

AXLA

Axcella Health Inc.

0.21

BCTX

BriaCell Therapeutics Corp.

0.21

AVRO

AVROBIO, Inc.

0.21

AXSM

Axsome Therapeutics, Inc.

0.2

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company’s drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.